{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:21:11Z","timestamp":1794590471897,"version":"4.9.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein that improves cardiopulmonary function in patients with pulmonary arterial hypertension (PAH) by selectively trapping activins and growth differentiation factors. However, the cellular and molecular mechanisms of ActRIIA-Fc action are incompletely understood. Here, we determined through genome-wide expression profiling that inflammatory and immune responses are prominently upregulated in the lungs of a Sugen-hypoxia rat model of severe angio-obliterative PAH, concordant with profiles observed in PAH patients. Therapeutic treatment with ActRIIA-Fc\u2014but not with a vasodilator\u2014strikingly reversed proinflammatory and proliferative gene expression profiles and normalized macrophage infiltration in diseased rodent lungs. Furthermore, ActRIIA-Fc normalized pulmonary macrophage infiltration and corrected cardiopulmonary structure and function in <jats:italic>Bmpr2<\/jats:italic> haploinsufficient mice subjected to hypoxia, a model of heritable PAH. Three high-affinity ligands of ActRIIA-Fc each induced macrophage activation in vitro, and their combined immunoneutralization in PAH rats produced cardiopulmonary benefits comparable to those elicited by ActRIIA-Fc. Our results in complementary experimental and genetic models of PAH reveal therapeutic anti-inflammatory activities of ActRIIA-Fc that, together with its known anti-proliferative effects on vascular cell types, could underlie clinical activity of sotatercept as either monotherapy or add-on to current PAH therapies.<\/jats:p>","DOI":"10.1038\/s41598-022-11435-x","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T10:33:06Z","timestamp":1652351586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension"],"prefix":"10.1038","volume":"12","author":[{"given":"Sachindra R.","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Karaca Atabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsing","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elitza","family":"Belcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Spaits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Grenha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Briscoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brantley R.","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselyne","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Pearsall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"11435_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","volume":"8","author":"RT Schermuly","year":"2011","unstructured":"Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R. & Grimminger, F. Mechanisms of disease: Pulmonary arterial hypertension. Nat. Rev. Cardiol. 8, 443\u2013455. https:\/\/doi.org\/10.1038\/nrcardio.2011.87 (2011).","journal-title":"Nat. Rev. Cardiol."},{"key":"11435_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","volume":"115","author":"M Rabinovitch","year":"2014","unstructured":"Rabinovitch, M., Guignabert, C., Humbert, M. & Nicolls, M. R. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 115, 165\u2013175. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.301141 (2014).","journal-title":"Circ. Res."},{"key":"11435_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/humu.22904","volume":"36","author":"RD Machado","year":"2015","unstructured":"Machado, R. D. et al. Pulmonary arterial hypertension: A current perspective on established and emerging molecular genetic defects. Hum. Mutat. 36, 1113\u20131127. https:\/\/doi.org\/10.1002\/humu.22904 (2015).","journal-title":"Hum. Mutat."},{"key":"11435_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5492","volume":"360","author":"T Thenappan","year":"2018","unstructured":"Thenappan, T., Ormiston, M. L., Ryan, J. J. & Archer, S. L. Pulmonary arterial hypertension: Pathogenesis and clinical management. BMJ 360, j5492. https:\/\/doi.org\/10.1136\/bmj.j5492 (2018).","journal-title":"BMJ"},{"key":"11435_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jacc.2018.09.089","volume":"73","author":"JC Kovacic","year":"2019","unstructured":"Kovacic, J. C. et al. Endothelial to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 190\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.089 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"11435_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cells9091965","author":"C Hiepen","year":"2020","unstructured":"Hiepen, C., Mendez, P. L. & Knaus, P. It takes two to tango: Endothelial TGF\u03b2\/BMP signaling crosstalk with mechanobiology. Cells https:\/\/doi.org\/10.3390\/cells9091965 (2020).","journal-title":"Cells"},{"key":"11435_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1183\/09059180.00005412","volume":"21","author":"J-L Vachi\u00e9ry","year":"2012","unstructured":"Vachi\u00e9ry, J.-L. & Gaine, S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur. Resp. Rev. 21, 313\u2013320. https:\/\/doi.org\/10.1183\/09059180.00005412 (2012).","journal-title":"Eur. Resp. Rev."},{"key":"11435_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/bph.13721","volume":"174","author":"GJ Maarman","year":"2017","unstructured":"Maarman, G. J., Schulz, R., Sliwa, K., Schermuly, R. T. & Lecour, S. Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: A review of current literature. Br. J. Pharmacol. 174, 497\u2013511. https:\/\/doi.org\/10.1111\/bph.13721 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"11435_CR9","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1126\/scisignal.aay4430","volume":"12","author":"M Morikawa","year":"2019","unstructured":"Morikawa, M. et al. The ALK-1\/SMAD\/ATOH8 axis attenuates hypoxic responses and protects against the development of pulmonary arterial hypertension. Sci. Signal 12, 4430. https:\/\/doi.org\/10.1126\/scisignal.aay4430 (2019).","journal-title":"Sci. Signal"},{"key":"11435_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000557","volume":"17","author":"C Hiepen","year":"2019","unstructured":"Hiepen, C. et al. BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGF\u03b2 responses and altered cell mechanics. PLoS Biol. 17, e3000557. https:\/\/doi.org\/10.1371\/journal.pbio.3000557 (2019).","journal-title":"PLoS Biol."},{"key":"11435_CR11","doi-asserted-by":"publisher","first-page":"H677","DOI":"10.1152\/ajpheart.91519.2007","volume":"295","author":"Y Song","year":"2008","unstructured":"Song, Y. et al. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am. J. Physiol. Heart Circ. Physiol. 295, H677\u2013H690. https:\/\/doi.org\/10.1152\/ajpheart.91519.2007 (2008).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"11435_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood-2010-05-285973","volume":"117","author":"VJ Burton","year":"2011","unstructured":"Burton, V. J. et al. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood 117, 333\u2013341. https:\/\/doi.org\/10.1182\/blood-2010-05-285973 (2011).","journal-title":"Blood"},{"key":"11435_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1164\/rccm.201408-1509OC","volume":"192","author":"E Soon","year":"2015","unstructured":"Soon, E. et al. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 192, 859\u2013872. https:\/\/doi.org\/10.1164\/rccm.201408-1509OC (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11435_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1161\/circulationaha.119.040629","volume":"140","author":"W Tian","year":"2019","unstructured":"Tian, W. et al. Phenotypically silent bone morphogenetic protein receptor 2 mutations predispose rats to inflammation-induced pulmonary arterial hypertension by enhancing the risk for neointimal transformation. Circulation 140, 1409\u20131425. https:\/\/doi.org\/10.1161\/circulationaha.119.040629 (2019).","journal-title":"Circulation"},{"key":"11435_CR15","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3390\/ijms19092585","volume":"19","author":"N Rol","year":"2018","unstructured":"Rol, N., Kurakula, K. B., Happe, C., Bogaard, H. J. & Goumans, M. J. TGF-\u03b2 and BMPR2 signaling in PAH: Two black sheep in one family. Int. J. Mol. Sci. 19, 2585. https:\/\/doi.org\/10.3390\/ijms19092585 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"11435_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.drudis.2018.12.001","volume":"24","author":"B Tielemans","year":"2019","unstructured":"Tielemans, B., Delcroix, M., Belge, C. & Quarck, R. TGF\u03b2 and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. Drug Discov. Today 24, 703\u2013716. https:\/\/doi.org\/10.1016\/j.drudis.2018.12.001 (2019).","journal-title":"Drug Discov. Today"},{"key":"11435_CR17","doi-asserted-by":"publisher","first-page":"46362","DOI":"10.1038\/srep46362","volume":"7","author":"D Verzola","year":"2017","unstructured":"Verzola, D. et al. Myostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment. Sci. Rep. 7, 46362. https:\/\/doi.org\/10.1038\/srep46362 (2017).","journal-title":"Sci. Rep."},{"key":"11435_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105339118","author":"H Deng","year":"2021","unstructured":"Deng, H. et al. Activation of Smad2\/3 signaling by low fluid shear stress mediates artery inward remodeling. Proc. Natl. Acad. Sci. U.S.A. https:\/\/doi.org\/10.1073\/pnas.2105339118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"11435_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg5060","author":"V Mehta","year":"2021","unstructured":"Mehta, V. et al. Mechanical forces regulate endothelial-to-mesenchymal transition and atherosclerosis via an Alk5-Shc mechanotransduction pathway. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abg5060 (2021).","journal-title":"Sci. Adv."},{"key":"11435_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082070","author":"P Esposito","year":"2021","unstructured":"Esposito, P. et al. Myostatin\/activin-A signaling in the vessel wall and vascular calcification. Cells https:\/\/doi.org\/10.3390\/cells10082070 (2021).","journal-title":"Cells"},{"key":"11435_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1165\/rcmb.2015-0391TR","volume":"54","author":"Y Aschner","year":"2016","unstructured":"Aschner, Y. & Downey, G. P. Transforming growth factor-\u03b2: Master regulator of the respiratory system in health and disease. Am. J. Respir. Cell Mol. Biol. 54, 647\u2013655. https:\/\/doi.org\/10.1165\/rcmb.2015-0391TR (2016).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"11435_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1165\/rcmb.2012-0470OC","volume":"49","author":"PD Upton","year":"2013","unstructured":"Upton, P. D., Davies, R. J., Tajsic, T. & Morrell, N. W. Transforming growth factor-\u03b2(1) represses bone morphogenetic protein-mediated Smad signaling in pulmonary artery smooth muscle cells via Smad3. Am. J. Respir. Cell Mol. Biol. 49, 1135\u20131145. https:\/\/doi.org\/10.1165\/rcmb.2012-0470OC (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"11435_CR23","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1074\/jbc.M115.713487","volume":"291","author":"S Aykul","year":"2016","unstructured":"Aykul, S. & Martinez-Hackert, E. Transforming growth factor-\u03b2 family ligands can function as antagonists by competing for type II receptor binding. J. Biol. Chem. 291, 10792\u201310804. https:\/\/doi.org\/10.1074\/jbc.M115.713487 (2016).","journal-title":"J. Biol. Chem."},{"key":"11435_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.814222","author":"P Andre","year":"2022","unstructured":"Andre, P. et al. Therapeutic approaches for treating pulmonary arterial hypertension by correcting imbalanced TGF-\u03b2 superfamily signaling. Front. Med. https:\/\/doi.org\/10.3389\/fmed.2021.814222 (2022).","journal-title":"Front. Med."},{"issue":"106","key":"11435_CR25","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1152\/japplphysiol.90719.2008","volume":"1985","author":"A Yndestad","year":"2009","unstructured":"Yndestad, A. et al. Elevated levels of activin A in clinical and experimental pulmonary hypertension. J. Appl. Physiol. 1985(106), 1356\u20131364. https:\/\/doi.org\/10.1152\/japplphysiol.90719.2008 (2009).","journal-title":"J. Appl. Physiol."},{"key":"11435_CR26","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.3390\/ijms19102957","volume":"19","author":"TV Kudryashova","year":"2018","unstructured":"Kudryashova, T. V. et al. Inhibitory antibodies against activin A and TGF-\u03b2 reduce self-supported, but not soluble factors-induced growth of human pulmonary arterial vascular smooth muscle cells in pulmonary arterial hypertension. Int. J. Mol. Sci. 19, 2957. https:\/\/doi.org\/10.3390\/ijms19102957 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"11435_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1161\/hypertensionaha.117.10350","volume":"71","author":"X Yu","year":"2018","unstructured":"Yu, X. et al. Growth differentiation factor 11 promotes abnormal proliferation and angiogenesis of pulmonary artery endothelial cells. Hypertension 71, 729\u2013741. https:\/\/doi.org\/10.1161\/hypertensionaha.117.10350 (2018).","journal-title":"Hypertension"},{"key":"11435_CR28","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1126\/scitranslmed.aaz5660","volume":"12","author":"L-M Yung","year":"2020","unstructured":"Yung, L.-M. et al. ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension. Sci. Transl. Med. 12, 5660. https:\/\/doi.org\/10.1126\/scitranslmed.aaz5660 (2020).","journal-title":"Sci. Transl. Med."},{"key":"11435_CR29","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41467-021-21961-3","volume":"12","author":"GRT Ryanto","year":"2021","unstructured":"Ryanto, G. R. T. et al. An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. Nat. Commun. 12, 1720. https:\/\/doi.org\/10.1038\/s41467-021-21961-3 (2021).","journal-title":"Nat. Commun."},{"key":"11435_CR30","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert, M. et al. Sotatercept for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 384, 1204\u20131215. https:\/\/doi.org\/10.1056\/NEJMoa2024277 (2021).","journal-title":"N. Engl. J. Med."},{"key":"11435_CR31","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri.2016.112","volume":"16","author":"W Chen","year":"2016","unstructured":"Chen, W. & ten Dijke, P. Immunoregulation by members of the TGF\u03b2 superfamily. Nat. Rev. Immunol. 16, 723\u2013740. https:\/\/doi.org\/10.1038\/nri.2016.112 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"11435_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102314","volume":"104","author":"I Morianos","year":"2019","unstructured":"Morianos, I., Papadopoulou, G., Semitekolou, M. & Xanthou, G. Activin-A in the regulation of immunity in health and disease. J. Autoimmun. 104, 102314. https:\/\/doi.org\/10.1016\/j.jaut.2019.102314 (2019).","journal-title":"J. Autoimmun."},{"key":"11435_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mce.2011.10.009","volume":"359","author":"DM de Kretser","year":"2012","unstructured":"de Kretser, D. M., O\u2019Hehir, R. E., Hardy, C. L. & Hedger, M. P. The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell Endocrinol. 359, 101\u2013106. https:\/\/doi.org\/10.1016\/j.mce.2011.10.009 (2012).","journal-title":"Mol. Cell Endocrinol."},{"key":"11435_CR34","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/circulationaha.109.927681","volume":"121","author":"K Abe","year":"2010","unstructured":"Abe, K. et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121, 2747\u20132754. https:\/\/doi.org\/10.1161\/circulationaha.109.927681 (2010).","journal-title":"Circulation"},{"key":"11435_CR35","doi-asserted-by":"publisher","first-page":"H243","DOI":"10.1152\/ajpheart.00728.2013","volume":"306","author":"M Toba","year":"2014","unstructured":"Toba, M. et al. Temporal hemodynamic and histological progression in Sugen5416\/hypoxia\/normoxia-exposed pulmonary arterial hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 306, H243-250. https:\/\/doi.org\/10.1152\/ajpheart.00728.2013 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"11435_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1164\/rccm.201607-1515PP","volume":"195","author":"S Bonnet","year":"2017","unstructured":"Bonnet, S. et al. Translating research into improved patient care in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 195, 583\u2013595. https:\/\/doi.org\/10.1164\/rccm.201607-1515PP (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11435_CR37","doi-asserted-by":"publisher","first-page":"14079","DOI":"10.1038\/ncomms14079","volume":"8","author":"LA Hurst","year":"2017","unstructured":"Hurst, L. A. et al. TNF\u03b1 drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nat. Commun. 8, 14079. https:\/\/doi.org\/10.1038\/ncomms14079 (2017).","journal-title":"Nat. Commun."},{"key":"11435_CR38","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/circulationaha.111.038125","volume":"125","author":"E Cahill","year":"2012","unstructured":"Cahill, E. et al. Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 125, 920\u2013930. https:\/\/doi.org\/10.1161\/circulationaha.111.038125 (2012).","journal-title":"Circulation"},{"key":"11435_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/mi.2015.84","volume":"9","author":"M Duan","year":"2016","unstructured":"Duan, M. et al. CD11b immunophenotyping identifies inflammatory profiles in the mouse and human lungs. Mucosal. Immunol. 9, 550\u2013563. https:\/\/doi.org\/10.1038\/mi.2015.84 (2016).","journal-title":"Mucosal. Immunol."},{"key":"11435_CR40","doi-asserted-by":"publisher","first-page":"L363","DOI":"10.1152\/ajplung.00212.2011","volume":"302","author":"JG Gomez-Arroyo","year":"2012","unstructured":"Gomez-Arroyo, J. G. et al. The monocrotaline model of pulmonary hypertension in perspective. Am. J. Physiol. Lung Cell Mol. Physiol. 302, L363-369. https:\/\/doi.org\/10.1152\/ajplung.00212.2011 (2012).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"11435_CR41","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.jacc.2004.09.044","volume":"44","author":"M Krenz","year":"2004","unstructured":"Krenz, M. & Robbins, J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J. Am. Coll. Cardiol. 44, 2390\u20132397. https:\/\/doi.org\/10.1016\/j.jacc.2004.09.044 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"11435_CR42","doi-asserted-by":"publisher","first-page":"8680","DOI":"10.1126\/scitranslmed.aau8680","volume":"11","author":"JD Roh","year":"2019","unstructured":"Roh, J. D. et al. Activin type II receptor signaling in cardiac aging and heart failure. Sci. Transl. Med. 11, 8680 (2019).","journal-title":"Sci. Transl. Med."},{"key":"11435_CR43","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1161\/01.cir.0000012754.72951.3d","volume":"105","author":"C Atkinson","year":"2002","unstructured":"Atkinson, C. et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672\u20131678. https:\/\/doi.org\/10.1161\/01.cir.0000012754.72951.3d (2002).","journal-title":"Circulation"},{"key":"11435_CR44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nm.3877","volume":"21","author":"L Long","year":"2015","unstructured":"Long, L. et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat. Med. 21, 777\u2013785. https:\/\/doi.org\/10.1038\/nm.3877 (2015).","journal-title":"Nat. Med."},{"key":"11435_CR45","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/circulationaha.110.978627","volume":"123","author":"E Vergadi","year":"2011","unstructured":"Vergadi, E. et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation 123, 1986\u20131995. https:\/\/doi.org\/10.1161\/circulationaha.110.978627 (2011).","journal-title":"Circulation"},{"key":"11435_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006674","author":"W Tian","year":"2013","unstructured":"Tian, W. et al. Blocking macrophage leukotriene B4 prevents endothelial injury and reverses pulmonary hypertension. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.3006674 (2013).","journal-title":"Sci. Transl. Med."},{"key":"11435_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.4049\/jimmunol.1303048","volume":"193","author":"KC El Kasmi","year":"2014","unstructured":"El Kasmi, K. C. et al. Adventitial fibroblasts induce a distinct proinflammatory\/profibrotic macrophage phenotype in pulmonary hypertension. J. Immunol. 193, 597\u2013609. https:\/\/doi.org\/10.4049\/jimmunol.1303048 (2014).","journal-title":"J. Immunol."},{"key":"11435_CR48","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.3390\/ijms19092534","volume":"19","author":"GR Willis","year":"2018","unstructured":"Willis, G. R., Fernandez-Gonzalez, A., Reis, M., Mitsialis, S. A. & Kourembanas, S. Macrophage immunomodulation: The gatekeeper for mesenchymal stem cell derived-exosomes in pulmonary arterial hypertension?\u00a0Int. J. Mol. Sci. 19, 2534. https:\/\/doi.org\/10.3390\/ijms19092534 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"11435_CR49","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.4049\/jimmunol.1900239","volume":"204","author":"YA Yu","year":"2020","unstructured":"Yu, Y. A. et al. Nonclassical monocytes sense hypoxia, regulate pulmonary vascular remodeling, and promote pulmonary hypertension. J. Immunol. 204, 1474\u20131485. https:\/\/doi.org\/10.4049\/jimmunol.1900239 (2020).","journal-title":"J. Immunol."},{"key":"11435_CR50","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.4049\/jimmunol.165.6.2997","volume":"165","author":"K Ogawa","year":"2000","unstructured":"Ogawa, K., Funaba, M., Mathews, L. S. & Mizutani, T. Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages. J. Immunol. 165, 2997\u20133003. https:\/\/doi.org\/10.4049\/jimmunol.165.6.2997 (2000).","journal-title":"J. Immunol."},{"key":"11435_CR51","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.4049\/jimmunol.177.10.6787","volume":"177","author":"K Ogawa","year":"2006","unstructured":"Ogawa, K., Funaba, M., Chen, Y. & Tsujimoto, M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J. Immunol. 177, 6787\u20136794. https:\/\/doi.org\/10.4049\/jimmunol.177.10.6787 (2006).","journal-title":"J. Immunol."},{"key":"11435_CR52","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1182\/blood-2010-09-306993","volume":"117","author":"E Sierra-Filardi","year":"2011","unstructured":"Sierra-Filardi, E. et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 117, 5092\u20135101. https:\/\/doi.org\/10.1182\/blood-2010-09-306993 (2011).","journal-title":"Blood"},{"key":"11435_CR53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","volume":"29","author":"SL Deshmane","year":"2009","unstructured":"Deshmane, S. L., Kremlev, S., Amini, S. & Sawaya, B. E. Monocyte chemoattractant protein-1 (MCP-1): An overview. J. Interferon. Cytokine Res. 29, 313\u2013326. https:\/\/doi.org\/10.1089\/jir.2008.0027 (2009).","journal-title":"J. Interferon. Cytokine Res."},{"key":"11435_CR54","doi-asserted-by":"publisher","first-page":"239715","DOI":"10.1242\/jcs.239715","volume":"133","author":"PD Upton","year":"2020","unstructured":"Upton, P. D. et al. Endothelial protective factors BMP9 and BMP10 inhibit CCL2 release by human vascular endothelial cells. J. Cell Sci. 133, 239715. https:\/\/doi.org\/10.1242\/jcs.239715 (2020).","journal-title":"J. Cell Sci."},{"key":"11435_CR55","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3390\/ijms18122563","volume":"18","author":"SP Didion","year":"2017","unstructured":"Didion, S. P. Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature. Int. J. Mol. Sci. 18, 2563. https:\/\/doi.org\/10.3390\/ijms18122563 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"11435_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","volume":"40","author":"CA Fielding","year":"2014","unstructured":"Fielding, C. A. et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40, 40\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.022 (2014).","journal-title":"Immunity"},{"key":"11435_CR57","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1172\/jci96462","volume":"128","author":"Y Tamura","year":"2018","unstructured":"Tamura, Y. et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. J. Clin. Invest. 128, 1956\u20131970. https:\/\/doi.org\/10.1172\/jci96462 (2018).","journal-title":"J. Clin. Invest."},{"key":"11435_CR58","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1183\/09031936.00174908","volume":"34","author":"N Selimovic","year":"2009","unstructured":"Selimovic, N. et al. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur. Respir. J. 34, 662\u2013668. https:\/\/doi.org\/10.1183\/09031936.00174908 (2009).","journal-title":"Eur. Respir. J."},{"key":"11435_CR59","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/circresaha.108.182014","volume":"104","author":"MK Steiner","year":"2009","unstructured":"Steiner, M. K. et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104, 236\u2013244. https:\/\/doi.org\/10.1161\/circresaha.108.182014 (2009).","journal-title":"Circ. Res."},{"key":"11435_CR60","doi-asserted-by":"publisher","first-page":"L1473","DOI":"10.1152\/ajplung.00197.2006","volume":"292","author":"M Hagen","year":"2007","unstructured":"Hagen, M. et al. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L1473-1479. https:\/\/doi.org\/10.1152\/ajplung.00197.2006 (2007).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"11435_CR61","doi-asserted-by":"publisher","first-page":"2000314","DOI":"10.1183\/13993003.00314-2020","volume":"55","author":"M Toshner","year":"2020","unstructured":"Toshner, M. & Rothman, A. M. K. IL-6 in pulmonary hypertension: Why novel is not always best. Eur. Respir. J. 55, 2000314. https:\/\/doi.org\/10.1183\/13993003.00314-2020 (2020).","journal-title":"Eur. Respir. J."},{"key":"11435_CR62","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1165\/rcmb.2009-0101TR","volume":"42","author":"CM Costello","year":"2010","unstructured":"Costello, C. M., Cahill, E., Martin, F., Gaine, S. & McLoughlin, P. Role of gremlin in the lung: Development and disease. Am. J. Respir. Cell Mol. Biol. 42, 517\u2013523. https:\/\/doi.org\/10.1165\/rcmb.2009-0101TR (2010).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"11435_CR63","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.016586","volume":"9","author":"L Meng","year":"2020","unstructured":"Meng, L. et al. Vital roles of gremlin-1 in pulmonary arterial hypertension induced by systemic-to-pulmonary shunts. J. Am. Heart Assoc. 9, e016586. https:\/\/doi.org\/10.1161\/jaha.120.016586 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"11435_CR64","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1042\/cs20171553","volume":"132","author":"C Lavoz","year":"2018","unstructured":"Lavoz, C. et al. Gremlin activates the Notch pathway linked to renal inflammation. Clin. Sci. (Lond.) 132, 1097\u20131115. https:\/\/doi.org\/10.1042\/cs20171553 (2018).","journal-title":"Clin. Sci. (Lond.)"},{"key":"11435_CR65","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.ajpath.2013.07.017","volume":"183","author":"L Ciuclan","year":"2013","unstructured":"Ciuclan, L. et al. Treatment with anti\u2013gremlin 1 antibody ameliorates chronic hypoxia\/SU5416\u2013induced pulmonary arterial hypertension in mice. Am. J. Pathol. 183, 1461\u20131473. https:\/\/doi.org\/10.1016\/j.ajpath.2013.07.017 (2013).","journal-title":"Am. J. Pathol."},{"key":"11435_CR66","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.healun.2014.09.011","volume":"34","author":"H Maruyama","year":"2015","unstructured":"Maruyama, H. et al. Endothelin-bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension. J. Heart Lung Transplant 34, 468\u2013478. https:\/\/doi.org\/10.1016\/j.healun.2014.09.011 (2015).","journal-title":"J. Heart Lung Transplant"},{"key":"11435_CR67","doi-asserted-by":"publisher","first-page":"H1322","DOI":"10.1152\/ajpheart.00136.2018","volume":"315","author":"T Thenappan","year":"2018","unstructured":"Thenappan, T., Chan, S. Y. & Weir, E. K. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 315, H1322\u2013H1331. https:\/\/doi.org\/10.1152\/ajpheart.00136.2018 (2018).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"11435_CR68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1165\/rcmb.2018-0275LE","volume":"61","author":"L Calvier","year":"2019","unstructured":"Calvier, L. et al. Chronic TGF-\u03b21 signaling in pulmonary arterial hypertension induces sustained canonical Smad3 pathways in vascular smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 61, 121\u2013123. https:\/\/doi.org\/10.1165\/rcmb.2018-0275LE (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"11435_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.7860\/jcdr\/2017\/21942.9914","volume":"11","author":"AV Balegadde","year":"2017","unstructured":"Balegadde, A. V., Vijan, V. & Thachathodiyl, R. A case series of young patients with completely reversed severe pulmonary hypertension. J. Clin. Diagn. Res. 11, 4\u20135. https:\/\/doi.org\/10.7860\/jcdr\/2017\/21942.9914 (2017).","journal-title":"J. Clin. Diagn. Res."},{"key":"11435_CR70","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1096\/fj.00-0343com","volume":"15","author":"L Taraseviciene-Stewart","year":"2001","unstructured":"Taraseviciene-Stewart, L. et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15, 427\u2013438. https:\/\/doi.org\/10.1096\/fj.00-0343com (2001).","journal-title":"FASEB J."},{"key":"11435_CR71","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1073\/pnas.0711263105","volume":"105","author":"RS Pearsall","year":"2008","unstructured":"Pearsall, R. S. et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc. Natl. Acad. Sci. U.S.A. 105, 7082\u20137087. https:\/\/doi.org\/10.1073\/pnas.0711263105 (2008).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"11435_CR72","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531\u2013543. https:\/\/doi.org\/10.1016\/j.cell.2010.07.011 (2010).","journal-title":"Cell"},{"key":"11435_CR73","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1080\/19420862.2016.1215786","volume":"8","author":"JR Apgar","year":"2016","unstructured":"Apgar, J. R. et al. Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody. MAbs 8, 1302\u20131318. https:\/\/doi.org\/10.1080\/19420862.2016.1215786 (2016).","journal-title":"MAbs"},{"key":"11435_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150606","volume":"11","author":"YR Yu","year":"2016","unstructured":"Yu, Y. R. et al. A protocol for the comprehensive flow cytometric analysis of immune cells in normal and inflamed murine non-lymphoid tissues. PLoS ONE 11, e0150606. https:\/\/doi.org\/10.1371\/journal.pone.0150606 (2016).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11435-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11435-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11435-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:31:59Z","timestamp":1669343519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11435-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11435"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11435-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.J., J.L., T.B., E.K.A., T.-H.K., M.L., E.B., M.S., R.G., M.C.M, J.L.F., K.W., S.D.B., M.J.A., B.R.H., R.C., R.S.P., P.A., R.K., and G.L. either\u00a0are\u00a0or were employees of Acceleron Pharma\u00a0Inc., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may have owned stock in the company. P.B.Y has served as a consultant for Acceleron Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7803"}}